HOME >> BIOLOGY >> NEWS
Experimental therapy stops allergic reactions in mice

The other receptor molecule is like a brake, explains senior author Andrew Saxon, M.D., director of the UCLA Asthma, Allergy, and Immunologic Disease Center. However, in this case, the brake only works when coupled with the gas pedal. Therefore, we constructed GE2 so that one end steps on the brake while the other end binds to the gas pedal. This cross-linking slows or stops the allergic reaction.

In laboratory tests on human mast cells and basophils, the higher the dose of GE2, the less histamine the cells released when stimulated by an allergen. In tests on mice, GE2 significantly reduced allergic skin reactions.

Although many more lab and animal studies will be necessary before this approach can be tested in humans, it has the potential to treat such diseases as allergic asthma, allergic rhinitis, chronic urticaria (hives), angioedema (hive-like swelling) and even the sometimes deadly anaphylaxis brought on by allergic reactions to certain foods such as peanuts, Dr. Saxon says.

GE2 is called a fusion protein because its two active parts are connected, or fused, by a linking molecule. As it is constructed now, GE2 contains generic active parts that indiscriminately block reactions to any allergen, Dr. Saxon says. However, a fusion protein like GE2 could be designed to contain a specific allergen such as a peanut protein and thereby block only allergic reactions to peanut. These allergen-specific fusion proteins could be used in allergy shots to make them safer and more effective: The patient could receive higher doses of allergen in the shot, making it more effective, without running the risk of suffering a dangerous allergic reaction, because the braking end of the fusion protein would stop that reaction.


'"/>

Contact: Jeff Minerd
jminerd@niaid.nih.org
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
30-Apr-2002


Page: 1 2

Related biology news :

1. Experimental drug shown to block mutant protein causing blood disease
2. Experimental smallpox DNA vaccine protects primates from lethal monkeypox
3. Experimental smallpox vaccine protects against monkeypox in nonhuman primates
4. Experimental Biology 2004 - Translating the Genome
5. Experimental Biology 2004 meets in Washington, D.C. April 17-21
6. Experimental hantavirus vaccine elicits strong antibody response in primates
7. Experimental cancer drugs may halt events that lead to cardiac hypertrophy and heart failure
8. Experimental Biology 2003 meets in San Diego April 11-15
9. Experimental Biology 2003 meets in San Diego April 11-15
10. Experimental gene switch increases lifespan with no ill effects
11. APS awards 44 minority travel fellowships to the Experimental Biology 2002 meeting

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/11/2019)... ... 11, 2019 , ... A new report published by the Family Equality Council ... 77% of those aged 18 to 35 already have or are considering having children, ... and older.(1) Among all LGBTQ prospective parents, 41% are considering assisted reproductive technology (ART) ...
(Date:3/9/2019)... ... March 07, 2019 , ... StressMarq ... stress research tools today announced the publication of its recent PCT patent ... antibody, still at a pre-clinical stage of development, moves the company into the ...
(Date:3/5/2019)... (PRWEB) , ... March 05, 2019 , ... Join this ... how a metadata-driven approach will help data analysts and bioinformaticians focus on data analysis ... unify data that can come from different source systems. Some sources of data include:, ...
Breaking Biology News(10 mins):
(Date:3/19/2019)... Calif. (PRWEB) , ... March 19, 2019 , ... ... Konica Minolta, Inc. (Konica Minolta) today announced the formation of their inaugural Scientific ... the advancement of precision medicine that takes into account individual variability in genes, ...
(Date:3/19/2019)... Switzerland (PRWEB) , ... March ... ... at Tel HaShomer, the largest hospital in Israel and the Middle East ... manufacturing using the state-of-the-art Cocoon™ manufacturing platform. The partnership will enable Sheba ...
(Date:3/18/2019)... ... 18, 2019 , ... For more than 15 years, USDM Life Sciences ... science companies to easily comply with FDA 21 CFR Part 11 and EMA EudraLex ... service delivering end-to-end GxP compliance from vendor audit through ongoing validation maintenance, including every ...
(Date:3/14/2019)... ... March 14, 2019 , ... ... in Oklahoma City, OK. EyeCRO joins the Department of Veterans Affairs, the Oklahoma ... Center as the fifth institution in Oklahoma to receive this prestigious endorsement. ...
Breaking Biology Technology:
Cached News: